Military gets new PTSD treatment option—but evidence is still emerging
H.R. 8764 — TREAT PTSD TRICARE Act · Filed by Scott Perry (R-PA) · Introduced May 12, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Department of Defense to offer stellate ganglion block (SGB)—a nerve-blocking injection used experimentally to treat PTSD symptoms—to all active-duty and reserve service members diagnosed with PTSD who enroll in TRICARE and consent to the procedure. The DoD must update its clinical practice guidelines within 180 days to include SGB as a therapy option and inform Congress of the update.
Why we flagged it
The bill's operative mechanism is a straightforward expansion of TRICARE benefits to include a specific emerging therapy for a defined population (PTSD-diagnosed service members). It is a healthcare access measure, not a deregulation, subsidy carve-out, or commemorative act.
What the text implies
- SGB is an emerging/experimental therapy with mixed clinical evidence; widespread DoD adoption may accelerate its use before long-term safety/efficacy data are mature, potentially exposing service members to off-label risks.
- The bill does not specify funding source or appropriation; implementation cost and budget impact on TRICARE are not addressed, creating potential fiscal uncertainty.
The full analysis lists 4 implications of this text.
Who stands to gain
healthcare providers administering SGB procedures; medical device/pharmaceutical suppliers of SGB materials